MET and lung cancer: Cinobufotalin combined with gefitinib suppresses A549 cell viability and promotes cell apoptosis by downregulating HGF protein expression and blocking c-Met gene amplification, indicating that cinobufotalin may delay the occurrence of gefitinib resistance in lung cancer cells.